LVW Advisors LLC Cuts Stock Position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB)

LVW Advisors LLC lessened its position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) by 1.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 632,516 shares of the company’s stock after selling 8,523 shares during the quarter. LVW Advisors LLC’s holdings in Anebulo Pharmaceuticals were worth $1,063,000 at the end of the most recent reporting period.

Wall Street Analyst Weigh In

Separately, Benchmark reiterated a “speculative buy” rating and issued a $8.00 price objective on shares of Anebulo Pharmaceuticals in a report on Tuesday, November 19th.

Insider Buying and Selling

In other Anebulo Pharmaceuticals news, Director Aron R. English acquired 10,101,010 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $0.99 per share, with a total value of $9,999,999.90. Following the transaction, the director now owns 15,467,300 shares in the company, valued at $15,312,627. The trade was a 188.23 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 85.90% of the stock is currently owned by insiders.

Anebulo Pharmaceuticals Price Performance

ANEB opened at $1.59 on Monday. Anebulo Pharmaceuticals, Inc. has a 12 month low of $0.80 and a 12 month high of $3.30. The stock has a market capitalization of $41.23 million, a price-to-earnings ratio of -5.30 and a beta of -1.14. The business has a fifty day moving average price of $1.50 and a 200 day moving average price of $1.85.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.